Moderate To Severe Systemic Lupus Erythematosus clinical trials

Explore recruiting moderate to severe systemic lupus erythematosus clinical trials.

Recruiting moderate to severe systemic lupus erythematosus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Systemic Lupus Erythematosus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Spain, Germany, Portugal, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPUS-1 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

France, Greece, Poland, Bulgaria, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)

Bulgaria, Romania, France, Germany, Spain, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Denmark, Hungary, Portugal, Italy, Norway, Greece +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus

Hungary, Spain, Bulgaria, Germany, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE

Belgium, Greece, France, Hungary, Portugal, Slovakia +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Moderate To Severe Systemic Lupus Erythematosus trials by city

Moderate To Severe Systemic Lupus Erythematosus in Toronto Moderate To Severe Systemic Lupus Erythematosus in Vancouver Moderate To Severe Systemic Lupus Erythematosus in Montreal Moderate To Severe Systemic Lupus Erythematosus in Calgary Moderate To Severe Systemic Lupus Erythematosus in Edmonton Moderate To Severe Systemic Lupus Erythematosus in Ottawa Moderate To Severe Systemic Lupus Erythematosus in Winnipeg Moderate To Severe Systemic Lupus Erythematosus in Quebec City Moderate To Severe Systemic Lupus Erythematosus in Hamilton Moderate To Severe Systemic Lupus Erythematosus in Kitchener Moderate To Severe Systemic Lupus Erythematosus in London Moderate To Severe Systemic Lupus Erythematosus in Halifax Moderate To Severe Systemic Lupus Erythematosus in New York Moderate To Severe Systemic Lupus Erythematosus in Los Angeles Moderate To Severe Systemic Lupus Erythematosus in Chicago Moderate To Severe Systemic Lupus Erythematosus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease